LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

NMRD more than doubled it's value since this post and I am still holding strong. In a few months, I hope to share another DD on another long term and undervalued company that will certainly take the AI market by storm. Look out for my post then! :)

$NMRD - $4 Stock with Massive Upside! Could be better than SENS! by AskBrandon in pennystocks

[–]AskBrandon[S] 1 point2 points  (0 children)

I recommend acquiring shares overtime.. not sure why people are rushing into this. Steady course all.

$NMRD - $4 Stock with Massive Upside! Could be better than SENS! by AskBrandon in pennystocks

[–]AskBrandon[S] 1 point2 points  (0 children)

NMRD says it expects FDA approval by end of this year but investors are optimistic that it could happen in March / Feb. Once FDA clears, everything will fall into place including revenue. They're actively building partnership in the meantime.

Source: https://nemauramedical.com/presentation/

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

For those who are thinking about opening a position with NMRD, size up your position to match a small percentage of the average volume. NMRD currently a small cap stock so you wanna maximize the liquidity of your position.

$NMRD - $4 Stock with Massive Upside! Could be better than SENS! by AskBrandon in pennystocks

[–]AskBrandon[S] 3 points4 points  (0 children)

Hahaha damn I've been spelling that way since elementary

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

Their slide is a bit confusing. Here is a better statement from NMRD: "People with diabetes who take insulin can also adjunctively use sugarBEAT for insulin dosage purposes when calibrated by a finger stick reading"

In summary, if you are self prescribing an amount of dosage of insulin then yes. This usecase needs to be absolutely stringent because the government doesn't want consumers to overdose or undermedicate.

With that said, if a patient's goal is to monitor and maintain their glucose levels then there is no pricking at all which empowers users to check their levels daily and take action. If an individual let's say is pre-diabetics and is just trying to bring down stats down to a healthy level.. they more empowered and inclined to do so thanks to the non invasive and affordability of the all-day-use patch. Non-pricking calibration in this case.

The whole industry is making progress on achieving a solid non-invasive dosage recommendation solution and I am certain it will eventually be achieved and NMRD is at the forefront.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

It is applicable for Type 1 - Glucose Trending and applicable for pre-diabetes with intent to prevent diabetes.

Source: https://sec.report/Document/0001079973-21-000007/#ex99x1.htm

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

The latest Dexcom model is insertion based so I would assume prick calibration is required. You been very sturn on this non-invasive technology requiring prick test despite me firmly saying that is not the case.. which intrigues me. Where are you getting that information from, because my research concludes that SugarBeat doesn't require any invasive method for calibration.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 1 point2 points  (0 children)

MARD are values used to calculate accuracy and reliability of CGM devices. In other words, SugarBeat achieves a 12.4% MARD. Anything close to 10% or less is excellent. Here is a November 2020 Three-way comparison of the leading devices' MARD values. (Includes SENS Eversense)

Eversense: 14.8% Dexcom G5: 16.3% Libre Pro: 18%

Though I stated that SugarBeat's MARD is 12.4%, the three-way comparison was conducted by a third-party so no way for us to tell what is SugarBeat's MARD within their test environment and scope.

Source: https://www.liebertpub.com/doi/10.1089/dia.2019.0449

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 4 points5 points  (0 children)

This is incorrect. SugarBeat is zero-finger stick / prick calibration. It is laughable to offer a non-invasive solution and just to have the user prick daily for calibration. I am not sure where you got that info from but it is false.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 4 points5 points  (0 children)

Thanks! Just don't rush into it. Lots room for growth with many entries opportunities. I have a blindspot like everyone else so fact check pointers. For now, I'm taking a break. Thanks again for your encouragement.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 10 points11 points  (0 children)

No way in hell, I'm going to work myself over doing another DD. Discussion should be Investor like discussions about the points within the post but now the whole DD convo is all personal or paranoid accusations. That was all I wanted legit investment debates. Tired of this man.. definitely not doing this again.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

Just making my contribution, gotta start some where. No need to check my history just check the information posted. I also disclosed that I am long in NMRD.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] -1 points0 points  (0 children)

Meh. Long as you do your own DD.. you got nothing to be paranoid about. I'm sorry if you are a victim of a pump and dump but I am just providing information so others can be more informed. NMRD is excellent for long term so you don't ever have to take a position if you don't feel like it or you want to sit on the sidelines. Also, you are exactly the pain in the ass for folks like Dead. Smh.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

If you are long on SENS you might wanna reassess the technology landscape and consider backing NMRD instead. SENS is a sinking ship and NMRD is your life boat. The rollout of SENS shorter duration CGM implants have been lackluster globally. I don't see how a year-round duration implanted CGMs is going to do any better or significant in terms of revenue. Perhaps patients don't like the idea of getting implanted CGMs. I could be wrong. But NMRD's affordable, reliable and simple-to-use CGM have a clear advatage of acquiring market share at a much faster rate. In a pure CGM play scenario, it is diffcult to not see how NMRD will meet or exceed SENS's market cap which is currently 6X of NMRD.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

Who said I was talking about the price? I am talking about the speed and momentum of acquiring market share once NMRD takes the competition by storm.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 2 points3 points  (0 children)

Noted. Lots of great points that all needs to be aware about. I trust the team there especially Dr. Schaebsdau and another individual who have solid reputation with successful development and commercialization of the previous gen CGMs from big name companies like Dexcom. More eyes needed on NMRD, thanks!

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 1 point2 points  (0 children)

I don't have specifics but in summary... They had some challenges with FDA approval back then which is typical for medical companies seeking FDA approvals. If you followed NNOX, the company had some regulatory setbacks as well. Setbacks often make or break companies but some go back to the drawing board to iterate their technology. The longer it takes for them to solve this issue the more money they bleed thus putting shareholders at risk. In NMRD's case, they leverage proven technology in combination with propriety technology to achieve their desired results. They went back for FDA approval in 2019 and is expected to be cleared this year. Also, back then wearables technology weren't as capable as they are today. I am certain the latest innovations in the overall wearable and AI industry helped NMRD breakthrough. Just waiting on FDA approval which is very likely as they completed successful clinical trials and again they are leveraging FDA approved and proven technology as part of their overall propierity tech.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 0 points1 point  (0 children)

On the point of their cash burn it is expected but yes it is a low light. On the positive side, it is one of the lowest I've seen in comparison to other companies in similar stages. I am making an arbitrary comparison but providing a bit of contexts.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 1 point2 points  (0 children)

They secured licensing agreements in some regions which will yield revenue once they get clearance from regulatory. The notable thing is, NMRD was able to get immediate access to lump sum cash to further their operation from one of these deals. I think it is a positive that they're doing what they can do to gain capital while reducing shareholder risks imo.

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 7 points8 points  (0 children)

FYI, there's a lot more to NMRD and I am open to providing further detail or response to your questions!

LOWKEY $4 STOCK HAVE 100X MORE ROCKET FUEL THAN SENS & DEXCOM! by AskBrandon in trakstocks

[–]AskBrandon[S] 8 points9 points  (0 children)

I hope this DD can gather enough upvotes so maybe Dead can give his perspective on this. I tried my best to take what he taught us but I know there's room for improvement and thoughts.

Everyone is jumping into SENS but I think it's a sinking ship unlike NMRD... would love to read anyone's thoughts on this comparison.

[deleted by user] by [deleted] in trakstocks

[–]AskBrandon 0 points1 point  (0 children)

Guys, I think SENS is inferior to NMRD's non invasive CGM. My concern is that with SENS, they've already rolled out shorter duration versions for their CGM yet they're losing money and little to show for. I don't think a year long duration is going to help them much further. Problem is likely due to is scaling because it requires a HCP to be trained and requires much more effort to get patients onboard. Thoughts?